FBRX vs. ADCT, MOLN, CYBN, CCCC, SCPH, IVA, HURA, GLSI, LRMR, and CGEN
Should you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include ADC Therapeutics (ADCT), Molecular Partners (MOLN), Cybin (CYBN), C4 Therapeutics (CCCC), scPharmaceuticals (SCPH), Inventiva (IVA), TuHURA Biosciences (HURA), Greenwich LifeSciences (GLSI), Larimar Therapeutics (LRMR), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry.
Forte Biosciences vs.
ADC Therapeutics (NYSE:ADCT) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.
ADC Therapeutics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.
ADC Therapeutics presently has a consensus price target of $7.75, indicating a potential upside of 559.57%. Forte Biosciences has a consensus price target of $22.58, indicating a potential upside of 242.69%. Given ADC Therapeutics' higher possible upside, equities research analysts clearly believe ADC Therapeutics is more favorable than Forte Biosciences.
41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 4.1% of ADC Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, ADC Therapeutics had 7 more articles in the media than Forte Biosciences. MarketBeat recorded 15 mentions for ADC Therapeutics and 8 mentions for Forte Biosciences. ADC Therapeutics' average media sentiment score of 0.36 beat Forte Biosciences' score of 0.17 indicating that ADC Therapeutics is being referred to more favorably in the media.
Forte Biosciences has a net margin of 0.00% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat Forte Biosciences' return on equity.
ADC Therapeutics received 31 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 68.89% of users gave ADC Therapeutics an outperform vote while only 62.00% of users gave Forte Biosciences an outperform vote.
Forte Biosciences has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
ADC Therapeutics beats Forte Biosciences on 11 of the 16 factors compared between the two stocks.
Get Forte Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Forte Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:FBRX) was last updated on 4/4/2025 by MarketBeat.com Staff
Buy FBRX Stock Free FBRX Stock Alerts